CardioDx, Inc.
2500 Faber Place
Palo Alto
California
94303
United States
Tel: 650-475-2788
Fax: 650-475-2799
Website: http://www.cardiodx.com/
Email: info@cardiodx.com
68 articles about CardioDx, Inc.
-
CardioDx Release: New Study Published In The American Journal Of Medicine Expands The Clinical Evidence Underscoring The Value Of The Corus CAD Blood Test To Help Safely Direct Cardiovascular Care
4/13/2017
-
CardioDx Release: PROMISE Substudy Results, Published In The American Heart Journal, Provide Independent Validation Of The Clinical Value Of The Corus(R) CAD Blood Test To Accurately Identify Patients With Obstructive CAD
2/6/2017
-
CardioDx Announces Final Endpoint Results From The PRESET Registry At The AHA Scientific Sessions 2016
11/15/2016
-
CardioDx Names Former Siemens Exec as New CEO
6/1/2016
-
CardioDx, Inc. Release: PROMISE Trial Substudy Demonstrates That the Corus CAD Blood Test Is Associated With Clinical Events Among Patients Being Evaluated For Suspected Obstructive Coronary Artery Disease
4/5/2016
-
Timothy Henn, Experienced Genomics Diagnostics And Life Sciences Executive, Joins CardioDx, Inc. As Chief Financial Officer
12/16/2015
-
CardioDx, Inc. Announces Positive Data From A Large Primary Care Registry On The Impact Of The Corus CAD Test In The Assessment Of Obstructive Coronary Artery Disease In Women
10/2/2015
-
CardioDx, Inc. Expands Patient Access To The Corus CAD Test Through National Agreement With Quest Diagnostics
9/16/2015
-
CardioDx, Inc. Announces Positive Results From Clinical Utility Study Evaluating The Corus CAD Blood Test's Influence On Clinical Decision-Making In The Assessment Of Obstructive Coronary Artery Disease In Women
4/2/2015
-
Cardiovascular Disease Diagnostic Company CardioDx, Inc. Withdraws IPO
12/29/2014
-
CardioDx, Inc. Raises $35 Million In Equity Financing
12/19/2014
-
CardioDx, Inc. Announces Results Of Study Demonstrating The Benefits Of The Corus CAD Gene Expression Test Use In An African American Patient Population
10/21/2014
-
CardioDx, Inc. Announces Results Of Study Demonstrating The Benefits Of The Corus CAD Gene Expression Test Use In An African American Patient Population
10/20/2014
-
Redwood City's CardioDx, Inc. Bags $21 Million As Biotech IPOs Hit Rough Patch
7/29/2014
-
CardioDx, Inc. Announces Aetna And Coventry Health Coverage For Corus® CAD Gene Expression Test
7/8/2014
-
CardioDx, Inc. Release: New Study Results Further Reinforce That The Corus® CAD Test Helps Primary Care Clinicians Make Effective Referral Decisions For Patients With Suspected Obstructive Coronary Artery Disease
5/5/2014
-
CardioDx, Inc. Resurrects IPO Dreams
5/2/2014
-
CardioDx, Inc. Announces New Leadership Appointments
4/29/2014
-
CardioDx, Inc. And Medison Israel Enter Into An Exclusive Corus® CAD Product Marketing And Sales Agreement
4/9/2014
-
CardioDx, Inc. Release: Study Finds the Corus® CAD Gene Expression Blood Test Influenced Primary Care Decision-Making In The Assessment Of Patients With Suspected Obstructive Coronary Artery Disease
3/11/2014